JP4307561B2 - 創傷の治癒 - Google Patents
創傷の治癒 Download PDFInfo
- Publication number
- JP4307561B2 JP4307561B2 JP53544198A JP53544198A JP4307561B2 JP 4307561 B2 JP4307561 B2 JP 4307561B2 JP 53544198 A JP53544198 A JP 53544198A JP 53544198 A JP53544198 A JP 53544198A JP 4307561 B2 JP4307561 B2 JP 4307561B2
- Authority
- JP
- Japan
- Prior art keywords
- lap
- wound
- use according
- tgf
- wounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000029663 wound healing Effects 0.000 title claims description 38
- 206010052428 Wound Diseases 0.000 claims abstract description 98
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 98
- 230000035876 healing Effects 0.000 claims abstract description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 50
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 50
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 9
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 230000036269 ulceration Effects 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 206010040943 Skin Ulcer Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 206010041899 Stab wound Diseases 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 239000000203 mixture Substances 0.000 abstract description 15
- 238000011282 treatment Methods 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 230000003176 fibrotic effect Effects 0.000 abstract description 3
- 239000003102 growth factor Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 231100000241 scar Toxicity 0.000 abstract description 3
- 230000003472 neutralizing effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000009772 tissue formation Effects 0.000 abstract description 2
- 102400000401 Latency-associated peptide Human genes 0.000 description 94
- 101800001155 Latency-associated peptide Proteins 0.000 description 94
- 108020004414 DNA Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000036573 scar formation Effects 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091005735 TGF-beta receptors Proteins 0.000 description 5
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 5
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 5
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 3
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 description 3
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000002283 elective surgery Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- -1 TGF-β1-5 Proteins 0.000 description 2
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9702943.3A GB9702943D0 (en) | 1997-02-13 | 1997-02-13 | Wound healing |
| GB9702943.3 | 1997-02-13 | ||
| PCT/GB1998/000316 WO1998035695A1 (en) | 1997-02-13 | 1998-02-13 | Wound healing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001511797A JP2001511797A (ja) | 2001-08-14 |
| JP2001511797A5 JP2001511797A5 (enExample) | 2005-09-08 |
| JP4307561B2 true JP4307561B2 (ja) | 2009-08-05 |
Family
ID=10807557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53544198A Expired - Fee Related JP4307561B2 (ja) | 1997-02-13 | 1998-02-13 | 創傷の治癒 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6319907B1 (enExample) |
| EP (1) | EP1009425B1 (enExample) |
| JP (1) | JP4307561B2 (enExample) |
| AT (1) | ATE223228T1 (enExample) |
| AU (1) | AU728851B2 (enExample) |
| CA (1) | CA2280873C (enExample) |
| DE (1) | DE69807710T2 (enExample) |
| DK (1) | DK1009425T3 (enExample) |
| ES (1) | ES2181165T3 (enExample) |
| GB (1) | GB9702943D0 (enExample) |
| PT (1) | PT1009425E (enExample) |
| WO (1) | WO1998035695A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756060B1 (en) * | 1996-09-19 | 2004-06-29 | Usbiomaterials Corp. | Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
| US6767891B2 (en) * | 2000-06-14 | 2004-07-27 | Chanda Zaveri | Peptides with wound healing activity |
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| US20030148924A1 (en) * | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
| US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| ATE429925T1 (de) * | 2000-07-31 | 2009-05-15 | Univ Bar Ilan | Methoden und pharmazeutische zusammensetzungen zur wundheilung |
| US20100129332A1 (en) * | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
| US20050164909A1 (en) * | 2003-07-16 | 2005-07-28 | The Ohio State University Research Foundation | Methods and reagents for treating inflammation and fibrosis |
| WO2005013885A2 (en) * | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| WO2007026356A2 (en) * | 2005-08-29 | 2007-03-08 | Healor Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| KR20150072458A (ko) | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
| EP2653166A3 (en) * | 2007-07-30 | 2014-08-27 | Healor Ltd. | Pharmaceutical composition and related methods |
| CN101855235B (zh) * | 2007-10-29 | 2013-04-24 | 赫里克斯生物医疗公司 | 保护性皮肤护理四肽 |
| CA2710375A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
| EP2252690A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| EP2234656A2 (en) | 2007-12-21 | 2010-10-06 | Coda Therapeutics, Inc. | Improved medical devices |
| US20100172217A1 (en) * | 2009-01-08 | 2010-07-08 | Von Bezold Ernst | System of Methods and Apparati for Handling and Modifying Information Energy and Matter by Formative Resonance |
| ES2601827T3 (es) * | 2009-02-24 | 2017-02-16 | Arava Bio-Tech Ltd. | Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones |
| WO2011083483A2 (en) | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| US9387183B2 (en) | 2011-12-28 | 2016-07-12 | Kuwait University | Method of treating diabetes-related impaired wound healing |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| US10232009B1 (en) * | 2017-09-29 | 2019-03-19 | Pro Sunfun Biotech Research And Development Co., Ltd. | Peptide for promoting wound healing, its composition and method of using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2068204C (en) * | 1989-11-22 | 2002-02-12 | Arthur Levinson | Latency associated peptides and uses therefor |
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| AU5587094A (en) * | 1992-10-26 | 1994-05-24 | Kirin Brewery Company, Limited | Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide |
| US6074840A (en) * | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
| AU710153B2 (en) * | 1994-03-29 | 1999-09-16 | Renovo Limited | Wound healing |
-
1997
- 1997-02-13 GB GBGB9702943.3A patent/GB9702943D0/en active Pending
-
1998
- 1998-02-13 US US09/367,262 patent/US6319907B1/en not_active Expired - Fee Related
- 1998-02-13 AT AT98903122T patent/ATE223228T1/de active
- 1998-02-13 AU AU59953/98A patent/AU728851B2/en not_active Ceased
- 1998-02-13 CA CA2280873A patent/CA2280873C/en not_active Expired - Fee Related
- 1998-02-13 ES ES98903122T patent/ES2181165T3/es not_active Expired - Lifetime
- 1998-02-13 EP EP98903122A patent/EP1009425B1/en not_active Expired - Lifetime
- 1998-02-13 WO PCT/GB1998/000316 patent/WO1998035695A1/en not_active Ceased
- 1998-02-13 DK DK98903122T patent/DK1009425T3/da active
- 1998-02-13 PT PT98903122T patent/PT1009425E/pt unknown
- 1998-02-13 JP JP53544198A patent/JP4307561B2/ja not_active Expired - Fee Related
- 1998-02-13 DE DE69807710T patent/DE69807710T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE223228T1 (de) | 2002-09-15 |
| AU728851B2 (en) | 2001-01-18 |
| US6319907B1 (en) | 2001-11-20 |
| CA2280873C (en) | 2010-04-06 |
| AU5995398A (en) | 1998-09-08 |
| DE69807710T2 (de) | 2003-06-05 |
| DE69807710D1 (de) | 2002-10-10 |
| DK1009425T3 (da) | 2002-10-14 |
| PT1009425E (pt) | 2002-11-29 |
| CA2280873A1 (en) | 1998-08-20 |
| HK1025504A1 (en) | 2000-11-17 |
| EP1009425A1 (en) | 2000-06-21 |
| JP2001511797A (ja) | 2001-08-14 |
| GB9702943D0 (en) | 1997-04-02 |
| WO1998035695A1 (en) | 1998-08-20 |
| EP1009425B1 (en) | 2002-09-04 |
| ES2181165T3 (es) | 2003-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4307561B2 (ja) | 創傷の治癒 | |
| JP3919212B2 (ja) | 線維障害の創傷治療処置 | |
| WO1998036061A2 (en) | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity | |
| JP2012211185A (ja) | 創傷治癒のためのｉｌ−１０関連ペプチド | |
| EP0855916B1 (en) | Pharmaceutical composition containing an activin stimulator | |
| AU2006268091B2 (en) | Promotion of epithelial regeneration | |
| US20110059896A1 (en) | Use of furin convertase inhibitors in the treatment of fibrosis and scarring | |
| EP0941108B1 (en) | Wound healing and treatment of fibrosis | |
| HK1025504B (en) | Use of latency associated peptide for the manufacture of a medicament for increasing wound healing | |
| HK1025732B (en) | Wound healing and treatment of fibrosis | |
| HK1073438B (en) | Furin inhibitors for use in the treatment of fibrosis and scarring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080618 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081031 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081218 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090407 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090430 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |